Abcuro
Breakthrough Therapies for Autoimmune Diseases and Cancer
- Headquarters
- Newton, Massachusetts
- Employees
- 51–200
- Founded
- 2015
- Business Model
- B2B
- Website
- abcuro.com
- Total Funding
- $407.3M
- Last Round
- $200.0M Series CFeb 2025
About
Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies targeting KLRG1 (Killer cell Lectin-like Receptor G1) for rare autoimmune diseases and cancers. Its lead candidate ulviprubart (ABC008) is in Phase 2/3 pivotal trials for Inclusion Body Myositis (IBM) and Phase 1 trials for T-Cell Large Granular Lymphocytic Leukemia (T-LGLL). The company has raised over $200M in Series C financing led by New Enterprise Associates with participation from Sanofi Ventures, RA Capital, and Bain Capital Life Sciences.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account